Drug-drug interaction potential in men treated with enzalutamide: Mind the gap
British Journal of Clinical Pharmacology Sep 12, 2017
Benoist GE, et al. Â In this assessment, the clinicians evaluated the prevalence of potential drug-drug interactions (DDIs) in metastatic castration resistant prostate cancer (mCRPC) patients treated with enzalutamide. They reported a high prevalence of potential DDIs. Between the three drug interaction compendia, the inclusion and grading of potential DDIs were highly variable. This problem requires a critical concern from physicians, nurses, and pharmacists, in order to implement intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins